Authum Investment & Infrastructure has entered into an agreement to invest in Serovia Pharma Private Limited, acquiring a 3% stake. The investment involves subscribing to compulsorily convertible preference shares. The deal is subject to customary closing conditions and corporate authorizations. This move aligns with Authum’s strategy of diversifying its investment portfolio.
Strategic Investment in Serovia Pharma
Authum Investment & Infrastructure Limited has announced an investment in Serovia Pharma Private Limited. The investment agreement, dated September 15, 2025, outlines the terms for Authum’s acquisition of a stake in the company.
Details of the Agreement
Authum Investment will subscribe to 18,95,053 partly paid-up compulsorily convertible preference shares of Serovia Pharma (“Series B CCPS”). This represents 3% of Serovia Pharma’s expanded share capital on a fully diluted basis.
Terms and Conditions
The agreement includes details regarding the operation, management, and governance of Serovia Pharma, as well as the relationship between shareholders. Consummation of the transaction is subject to certain pre-closing actions and corporate authorizations.
Consideration and Payment Terms
The primary infusion amounts to INR 3,000,001,553 to subscribe to Serovia Pharma shares. Each share has a face value of INR 10, along with a premium of INR 1573.07, aggregating to INR 1583.07 (“Subscription Price”). 50% of the subscription amount (INR 150,00,00,776.50) is payable on application, while the remaining 50% is payable on call by Serovia Pharma.
Serovia Pharma Overview
Serovia Pharma, incorporated on July 19, 2025, will focus on developing, manufacturing, and distributing pharmaceutical products globally. It currently has a presence in India and plans to expand to Cyprus and the US.
Source: BSE
